• No results found

Cover Page The handle

N/A
N/A
Protected

Academic year: 2021

Share "Cover Page The handle"

Copied!
9
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

The handle http://hdl.handle.net/1887/54687 holds various files of this Leiden University dissertation

Author: Broekman, Winifred

Title: Mesenchymal stromal cell treatment for COPD : experimental and clinical studies

Issue Date: 2017-09-07

(2)

MESENCHYMAL STROMAL CELL TREATMENT FOR COPD

EXPERIMENTAL AND CLINICAL STUDIES

WINIFRED BROEKMAN

(3)

Cover: Tjade Bouma

Layout and printing: Gildeprint, Enschede

Copyright 2017 Winifred Broekman, Leiden, the Netherlands. All rights reserved. No part of this thesis may be reproduced or transmitted, in any form or by any means, without prior written permission of the author.

(4)

MESENCHYMAL STROMAL CELL TREATMENT FOR COPD

EXPERIMENTAL AND CLINICAL STUDIES

PROEFSCHRIFT

ter verkrijging van

de graad van Doctor aan de Universiteit Leiden, op gezag van Rector Magnificus prof. mr. C.J.J.M. Stolker,

volgens besluit van het College voor Promoties te verdedigen op donderdag 7 september 2017

klokke 13:45 uur

door

WINIFRED BROEKMAN

geboren te Amsterdam in 1982

(5)

SPONSORING: 8/7 Consultancy, Chiesi, Chipsoft

(6)

“What if I’ve forgotten the most important thing?”

HARUKI MURAKAMI – Norwegian Wood, 1987

Voor Els

(7)
(8)

TABLE OF CONTENTS

CHAPTER 1: GENERAL INTRODUCTION

CHAPTER 2: Cigarette smoke modulates repair and innate immunity following injury to airway epithelial cells

G.D. Amatngalim*, W. Broekman*, N.M. Daniel, E.P.M. van der Vlugt, A. van Schadewijk, C. Taube, P.S. Hiemstra (* contributed equally)

Plos One, 2016 Nov 9; 11 (11): e0166255

CHAPTER 3: TNF-α and IL-1β-activated human mesenchymal stromal cells increase airway epithelial wound healing in vitro via activation of the epidermal growth factor receptor

W. Broekman, G.D. Amatngalim, Y. de Mooij-Eijk, J. Oostendorp, H. Roelofs, C. Taube, J. Stolk, P.S. Hiemstra

Respiratory Research, 2016 Jan 11; 17:3

CHAPTER 4: Functional characterization of bone marrow-derived mesenchymal stromal cells from COPD patients

W. Broekman, H. Roelofs, M.C. Zarcone, C. Taube, J. Stolk, P.S. Hiemstra

ERJ Open Research, 2016 Jun 28; 2 (2)

CHAPTER 5: A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema

J. Stolk*, W. Broekman*, T. Mauad, J.J. Zwaginga, H. Roelofs, W.E. Fibbe, J. Oostendorp, I. Bajema, M.I.M. Versteegh, C. Taube, P.S. Hiemstra (* contributed equally)

Quarterly Journal of Medicine, 2016 May 109 (5): 331-6

CHAPTER 6: Mesenchymal stromal cells: a novel therapy for the treatment of chronic obstructive pulmonary disease?

W. Broekman, P.P.S.J. Khedoe, K. Schepers, H. Roelofs, J. Stolk, P.S. Hiemstra

Under review

CHAPTER 7: SUMMARY AND GENERAL CONCLUSION

ADDENDUM: Nederlandstalige samenvatting Overzicht publicaties

Curriculum vitae Dankwoord

9 21

43

65

85

103

125

147 154 155 156

(9)

Referenties

GERELATEERDE DOCUMENTEN

Co-infusion of ex vivo expanded, parental mesenchymal stromal cells prevents life-threatening acute GvHD, but does not reduce the risk of graft failure in pediatric patients

We report data suggesting that exposure to multiple infusions of haploidentical MSCs can be administered in children undergoing HSCT after a myeloablative regimen without

CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk of graft versus host disease after HLA identical stem cell transplantation in humans. Chronic

Third party mesenchymal stromal cell infusions fail to induce tissue repair despite successful control of severe grade IV acute graft versus host disease in a child with

(A) PBMC (1.5 × 10 5 per well) from normal donors were stimulated with irradiated (irr) allogeneic (allo) PBMC, irr autologous (autol) LCL, pp65-peptides or recombinant Ad5

However, associated problems of graft dysfunction, delayed immune reconstitution as well as steroid refractory acute graft versus host disease, reduce the effectiveness of these

Allogeneic 3 rd party bone marrow derived MSCs (Prochymal®) for the treatment of steroid refractory grade II-IV acute graft versus host disease following allogeneic hematopoietic

In Hoofdstuk 7 wordt de uitkomst beschreven van een Fase II onderzoek naar het gebruik van MSCs bij patiënten (zowel kinderen als volwassenen) met ernstige, graad II-IV,